Association of gene polymorphisms with chronic kidney disease in high- or low-risk subjects defined by conventional

Tetsuro Yoshida1, Kimihiko Kato, Kiyoshi Yokoi

  • 1Department of Cardiovascular Medicine, Inabe General Hospital, Inabe, Japan.

Insights

Genetic variants influence chronic kidney disease (CKD) risk differently in high-risk (hypertension/diabetes) versus low-risk individuals. Identifying these specific genetic polymorphisms aids in personalized CKD prevention strategies.

Area of Science:

  • Genetics
  • Nephrology
  • Personalized Medicine

Background:

  • Chronic kidney disease (CKD) affects millions globally, with genetic predisposition playing a significant role.
  • Conventional risk factors like hypertension and diabetes mellitus are well-established, but genetic underpinnings require further elucidation.
  • Understanding genetic susceptibility is crucial for developing targeted prevention strategies.

Purpose of the Study:

  • To identify specific genetic polymorphisms associated with CKD susceptibility in Japanese individuals.
  • To differentiate genetic risk factors between subjects with high-risk (hypertension and diabetes) and low-risk profiles.
  • To explore the potential for personalized CKD prevention based on genetic information.

Main Methods:

  • Genotyping of 296 polymorphisms in 202 candidate genes was performed on 2828 Japanese individuals (434 CKD cases, 2394 controls).
  • Subjects were stratified into high-risk (hypertension and diabetes) and low-risk (no conditions) groups.
  • Statistical analyses, including Chi-square tests and multivariable logistic regression, were used to identify significant associations (P<0.05).

Main Results:

  • Ten polymorphisms were significantly associated with CKD prevalence, with distinct sets identified for high-risk and low-risk groups.
  • The MMP1 (-519A>G) polymorphism showed the strongest association in high-risk subjects.
  • The TGFBR2 (1167C>T) polymorphism was most significantly associated with CKD in low-risk individuals.

Conclusions:

  • Genetic polymorphisms associated with CKD susceptibility differ between high-risk and low-risk individuals.
  • Stratification by conventional risk factors is essential for identifying relevant genetic markers for CKD.
  • These findings support the development of personalized CKD prevention strategies informed by genetic data.

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...